Inventiva Announces FDA Lifts Target Class Clinical Hold on which Allows LongTerm Clinical Studies with Lanifibranor in NASH

Inventiva Announces FDA Lifts Target Class Clinical Hold on which Allows Long-Term Clinical Studies with Lanifibranor in NASH

Daix (France), May 23, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the U.S. Food and Drug Administration (FDA) has lifted for lanifibranor the clinical hold in place on the peroxisome proliferator-activated …

More From BioPortfolio on "Inventiva Announces FDA Lifts Target Class Clinical Hold on which Allows Long-Term Clinical Studies with Lanifibranor in NASH"